TRAP-AD - Orangeburg, NY

Back to Study

Details

Location:
Age: 65 to 85
Duration: 5-7 months
Visits: Approximately 31

Click Here to Learn More

Eligibility Requirements

Diagnosis of amnestic Mild Cognitive Impairment (aMCI) or early Alzheimer’s
Currently resides in the greater New York City or Rockland County areas
Has at least a high school diploma/12 years of education
Does not have a history of brain tumor, MRI evidence of serious neurological disorders such as epilepsy, ALS, Parkinson’s disease, MS, Tourette syndrome, or history of significant cardiovascular or cerebrovascular disease.

Enter Contact Info

Please provide your contact information and a member of the study team will contact you to follow up.

First Name *

Last Name *

Phone Number *

Email *

I have reviewed the eligibility requirements *

Diagnosis of amnestic Mild Cognitive Impairment (aMCI) or early Alzheimer’s
Currently resides in the greater New York City or Rockland County areas
Has at least a high school diploma/12 years of education
Does not have a history of brain tumor, MRI evidence of serious neurological disorders such as epilepsy, ALS, Parkinson’s disease, MS, Tourette syndrome, or history of significant cardiovascular or cerebrovascular disease.

I authorize the release of my contact information to the study team. *

I'm Not Ready

Thank you for your interest in this study. You're bringing us one step closer to our goal of ending Alzheimer's

Your contact information will be shared with the study team. If you have any questions, please contact the study team:

Medical University of South Carolina (MUSC)

Email: [email protected]

About the Study:

The TRAP-AD study is investigating an experimental treatment device for amnestic Mild Cognitive Impairment (aMCI) and early Alzheimer’s disease in a randomized clinical trial of 8 weeks of transcranial

photobiomodulation (tPBM) or sham (placebo) treatment. The t-PBM treatment stimulates

certain parts of the brain that are thought to be affected in memory impairment and may improve cognition in adults with aMCI and early Alzheimer’s.

Purpose:

The TRAP-AD study will test whether an experimental treatment device that uses near-infrared light therapy will lead to improvement in cognition in adults with amnestic Mild Cognitive Impairment (aMCI) and early Alzheimer’s.

What is Involved:

The tPBM device uses near-infrared light to stimulate areas of the brain near the forehead; it is a non-pharmacologic investigational treatment. Participants will first complete an assessment of medical history and memory to verify eligibility, undergo medical imaging procedures, and will then be randomized to either t-PBM or sham (placebo) treatment for 8 weeks (3 sessions per week, approximately 30-minute visit time per session). Following treatment, cognitive symptoms will be assessed two additional times to detect any improvement.

Participants will be compensated for their time.

Click Here to Learn More